Drug | Indication | Stage | RYZ101 (225Ac DOTATATE) |
Neuroendocrine Tumors | Clinical Trials (Phase 1-3) |
---|---|---|
RYZ101 (225Ac DOTATATE) |
Small Cell Lung Cancer | Clinical Trials (Phase 1-3) |
Glypican-3, GPC3 (Novel Peptide) |
Liver Cancer | Clinical imaging, IND enabling |
Program A (Novel Small Molecule) |
Multiple Solid Tumors | Clinical imaging, IND enabling |
Program B (Novel Peptide) |
Multiple Solid Tumors | Clinical imaging, IND enabling |
Program C (Novel Peptide) |
Multiple Solid Tumors | Lead Optimization |
Program D (Novel Peptide) |
Multiple Solid Tumors | Discovery |
Other Programs (Peptide/Small Molecules) |
Multiple Solid Tumors | Discovery |

Pipeline Overview
Our Approach Has Created an Innovative Pipeline
in Targeted Radiopharmaceuticals